Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Stevanato Group S.p.A.NYSE: STVN

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of €24.19M rose 12.2% year over year, ahead of the -22.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.9% from the prior quarter. Over 3 fiscal years it compounded at +11.0% a year.

Context

  • Depreciation & amortization amounted to 7.8% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12.2% holds above the trailing-twelve-month pace of -22.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€24.19M-1.9% QoQ
Last fiscal yearDec 2025
€88.57M+9.8% YoY
LTMJun 2026
€95.21M-22.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.2%——
1 year+9.8%——
3-year CAGR+11.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the cash flow

Latest · FY2025
88.57M EUR
Year-over-year change
+9.8%
4-year CAGR
+12.0%

Depreciation & Amortization vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -22.5% is the 8th highest of 10, against a peer median of +3.1%.
  • Depreciation & amortization amounts to 7.8% of revenue for STVN, versus a peer median of 6.4%.
STVN Competitors
Depreciation & Amortization for STVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVTRAvantor, Inc.LTM Jun 2026$418.4M USD+3.1%+0.4%6.4%
BLCOBausch + Lomb CorporationLTM Jun 2026$411M USD-4.2%+3.6%7.7%
ATRAptarGroup, Inc.LTM Jun 2026$307.18M USD+13.8%+7.1%7.8%
TFXTeleflex IncorporatedLTM Jun 2026$181.49M USD-33.6%-8.3%7.0%
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 2026$158.41M USD-11.8%-7.0%1.0%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$136.48M USD+3.5%+13.5%8.5%
STVNStevanato Group S.p.A.LTM Jun 2026€95.21M EUR-22.5%+11.0%7.8%
CHEChemed CorporationLTM Jun 2026$66.42M USD+4.1%+3.1%2.6%
MASIMasimo CorporationLTM Apr 2026$38.2M USD-62.4%-34.2%2.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$9.94M USD+16.8%+27.2%1.3%
NUVLNuvalent, Inc.LTM Mar 2026$0 USD———
Peer median (excluding STVN) —+3.1%+3.1%6.4%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income165.67M187.64M189.55M160.29M134.32M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(41.63M)(117.74M)(102.48M)(17.41M)48.63M
Accounts Receivables(54.77M)(46.42M)(93.86M)(3.83M)855.83K
Inventory(31.2M)(107.37M)(113.59M)12.31M(39.82M)
Accounts Payables44.34M36.05M104.97M(25.89M)87.59M
Other Working Capital00000
Other Non-Cash Items(47.09M)(31.41M)(60.34M)(67.76M)3.27M
Operating Cash Flow133.34M103.31M105.21M155.78M274.79M
Capital Expenditures(113.18M)(243.13M)(441.93M)(313.57M)(253.35M)
Acquisitions (Net)14.81M0(3.59M)(175K)1.79M
Purchases of Investments00000
Sales of Investments773K31K00241.09K
Other Investing Activities(4.32M)(7.95M)15.6M(7.44M)0
Investing Cash Flow(96.43M)(242.95M)(421.22M)(310.21M)(262.15M)
Debt Repayment(120.18M)(31.04M)172.57M27.91M41.38M
Common Stock Issued380.09M00169.77M0
Common Stock Repurchased00000
Dividends Paid(11.2M)(13.5M)(14.29M)(14.46M)(14.16M)
Other Financing Activities6.13M0(250K)0(6.03M)
Financing Cash Flow254.85M(44.54M)158.03M183.22M21.19M
Effect of Forex Changes3.68M1.88M(1.16M)(115K)10.11M
Net Change in Cash295.44M(182.3M)(159.14M)28.67M43.94M
Free Cash Flow20.16M(139.82M)(336.72M)(157.8M)21.44M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.